Gilead, Cognizant
Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
The stock's fall snapped a two-day winning streak.
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...
Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
This was the stock's second consecutive day of gains.
Zacks.com on MSN1d
Gilead Sciences (GILD) Stock Dips While Market Gains: Key FactsIn the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback